

## Adalimumab

Section	Indications
<p><b>Immunomodulators for non-malignant disease</b>            Parenteral &gt; General injections &gt; SC: 40 mg per 0.8 mL; 40 mg per 0.4 mL;            10 mg per 0.2 mL; 20 mg per 0.4 mL</p>	<ul style="list-style-type: none"> <li>Axial spondyloarthritis</li> <li>Crohn disease site</li> <li>Rheumatoid arthritis</li> </ul>

## Azathioprine

Section	Indications
<p><b>Immunomodulators for non-malignant disease</b>            Parenteral &gt; General injections &gt; IV: 50 mg in vial powder for injection (as sodium salt); 100 mg in vial powder for injection (as sodium salt)            Oral &gt; Liquid: 10 mg per mL            Oral &gt; Solid &gt; tablet: 25 mg; 50 mg (scored)            Oral &gt; Solid &gt; tablet: 50 mg (scored)</p>	<ul style="list-style-type: none"> <li>Failure or rejection of transplanted organs or tissues</li> <li>Relapsing-remitting multiple sclerosis</li> </ul>

## Certolizumab pegol

Section	Indications
<b>Immunomodulators for non-malignant disease</b>	<ul style="list-style-type: none"> <li>Therapeutic equivalent to adalimumab pour Axial spondyloarthritis</li> <li>Therapeutic equivalent to adalimumab pour Crohn disease site</li> <li>Therapeutic equivalent to adalimumab pour Rheumatoid arthritis</li> </ul>

## Ciclosporin

Section	Indications
<p><b>Immunomodulators for non-malignant disease</b>            Parenteral &gt; General injections &gt; IV: 50 mg per mL in 1 mL ampoule concentrate for injection            Oral &gt; Liquid: 100 mg per mL            Oral &gt; Solid &gt; capsule: 25 mg</p>	<ul style="list-style-type: none"> <li>Failure or rejection of transplanted organs or tissues</li> </ul>

## Etanercept

Section	Indications
Immunomodulators for non-malignant disease	Therapeutic equivalent to <b>adalimumab</b> pour <b>Axial spondyloarthritis</b>
	Therapeutic equivalent to <b>adalimumab</b> pour <b>Crohn disease site</b>
	Therapeutic equivalent to <b>adalimumab</b> pour <b>Rheumatoid arthritis</b>

## Fingolimod

Section	Indications
Immunomodulators for non-malignant disease Oral > Solid: 0.25 mg; 0.5 mg	<b>Relapsing-remitting multiple sclerosis</b>

## Golimumab

Section	Indications
Immunomodulators for non-malignant disease	Therapeutic equivalent to <b>adalimumab</b> pour <b>Axial spondyloarthritis</b>
	Therapeutic equivalent to <b>adalimumab</b> pour <b>Crohn disease site</b>
	Therapeutic equivalent to <b>adalimumab</b> pour <b>Rheumatoid arthritis</b>

## Infliximab

Section	Indications
Immunomodulators for non-malignant disease	Therapeutic equivalent to <b>adalimumab</b> pour <b>Axial spondyloarthritis</b>
	Therapeutic equivalent to <b>adalimumab</b> pour <b>Crohn disease site</b>
	Therapeutic equivalent to <b>adalimumab</b> pour <b>Rheumatoid arthritis</b>

## Methotrexate

Section	Indications
Immunomodulators for non-malignant disease Parenteral > General injections > SC: pre-filled syringe in multiple strengths	Crohn disease site Psoriatic arthritis

## Tacrolimus

Section	Indications
Immunomodulators for non-malignant disease Parenteral > General injections > IV: 5 mg per mL in 1 mL vial  Oral > Liquid: 0.2 mg granules for oral suspension; 1 mg granules for oral suspension  Oral > Solid: 0.5 mg (immediate-release); 0.75 mg (immediate-release); 1 mg (immediate-release); 2 mg (immediate-release); 5 mg (immediate-release)	Failure or rejection of transplanted organs or tissues